tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk Tirzepatide Improves HFpEF Symptoms and

The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment

Finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. Kerendia can cause some mild side effects: Low blood pressure

So if you are on your first injection and wondering why the scale has not moved, that is expected

Instead, they used the Gila monster discovery as a blueprint for synthetic and semi-synthetic compounds

I atrophied a lot when using it And another commenter had this to say: I did try Ozempic